AWH · Aspira Women'S Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.97M | - | $2.31M | $2.40M | $2.28M | - | $2.26M | $2.49M | $2.15M | - |
| Cost of Revenue | $896.0K | - | $922.0K | $870.0K | $719.0K | - | $902.0K | $1.00M | $939.0K | - |
| Gross Profit | $1.07M | - | $1.38M | $1.53M | $1.56M | - | $1.35M | $1.42M | $1.21M | - |
| R&D | $1.23M | - | $739.0K | $704.0K | $973.0K | - | $908.0K | $952.0K | $906.0K | - |
| SG&A | $1.50M | - | $1.54M | $1.96M | $2.74M | - | $2.05M | $2.73M | $3.13M | - |
| Total Operating Expenses | $3.27M | - | $2.96M | $3.34M | $4.80M | - | $5.10M | $5.81M | $5.92M | - |
| D&A | - | - | - | - | - | - | - | - | $29.0K | - |
| Operating Income | ($2.20M) | - | ($1.58M) | ($1.81M) | ($3.24M) | - | ($3.74M) | ($4.39M) | ($4.71M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | $676.0K | - | ($4.89M) | ($2.67M) | ($1.85M) | - | ($3.55M) | ($3.53M) | ($4.63M) | - |
| EPS - Basic | $0.02 | - | ($0.13) | ($0.07) | ($0.09) | - | ($0.23) | ($0.28) | ($0.39) | - |
| EPS - Diluted | ($0.05) | - | ($0.13) | ($0.07) | ($0.09) | - | ($0.23) | ($0.28) | ($0.39) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.34M | $1.75M | $3.81M | $1.54M | $3.31M | $1.77M | $2.13M | $962.0K | $3.41M | $2.60M |
| Accounts Receivable | $1.42M | $1.21M | $1.32M | $1.28M | $1.10M | $990.0K | $1.25M | $1.45M | $1.53M | $1.46M |
| Inventory | $292.0K | $256.0K | $282.0K | $273.0K | $260.0K | $326.0K | $290.0K | $226.0K | $236.0K | $227.0K |
| Accounts Payable | $1.97M | $1.24M | $1.81M | $1.74M | $1.45M | $2.17M | $2.55M | $1.94M | $1.64M | $1.26M |
| Current Assets | $3.79M | $4.06M | $5.83M | $3.69M | $5.39M | $4.18M | $4.11M | $3.25M | $6.12M | $5.28M |
| Total Assets | $5.09M | $5.46M | $7.30M | $4.93M | $6.72M | $5.49M | $4.76M | $3.96M | $7.16M | $6.26M |
| Current Liabilities | $5.59M | $3.46M | $4.20M | $4.10M | $3.79M | $5.47M | $5.47M | $5.46M | $5.29M | $5.12M |
| Long-term Debt | $980.0K | $1.04M | $1.10M | $1.16M | $1.22M | $1.28M | $1.33M | $1.26M | $1.35M | $1.43M |
| Total Liabilities | $11.29M | $12.39M | $11.64M | $7.62M | $6.78M | $8.05M | $7.28M | $7.67M | $8.53M | $8.63M |
| Stockholders' Equity | ($6.21M) | ($6.93M) | ($4.34M) | ($2.69M) | ($60.0K) | ($2.56M) | ($2.52M) | ($3.71M) | ($1.36M) | ($2.37M) |
| Retained Earnings | ($543.50M) | ($544.18M) | ($540.81M) | ($535.92M) | ($533.25M) | ($531.40M) | ($530.01M) | ($526.46M) | ($522.93M) | ($518.30M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($359.0K) | - | - | - | ($3.10M) | - | - | - | ($4.43M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($20.0K) | - |
| Financing Cash Flow | ($52.0K) | - | - | - | $4.64M | - | - | - | $5.27M | - |
| CapEx | - | - | - | - | - | - | - | - | $20.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($4.45M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 54.4% | - | 60.0% | 63.8% | 68.5% | - | 60.0% | 57.0% | 56.4% | - |
| Operating margin | -112.0% | - | -68.5% | -75.3% | -142.2% | - | -165.9% | -176.4% | -218.8% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -217.4% | - |
| Net margin | 34.4% | - | -212.2% | -110.9% | -81.3% | - | -157.2% | -141.7% | -215.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -206.7% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.96 | - |
| R&D / Revenue | 62.3% | - | 32.1% | 29.3% | 42.7% | - | 40.2% | 38.2% | 42.1% | - |
| SG&A / Revenue | 76.5% | - | 66.8% | 81.6% | 120.3% | - | 90.7% | 109.4% | 145.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | 13.3% | - | -67.1% | -54.0% | -27.6% | - | -74.5% | -89.1% | -64.6% | - |
| Return on equity | -10.9% | - | 112.6% | 99.3% | 3088.3% | - | 140.8% | 95.2% | 339.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.68 | 1.17 | 1.39 | 0.90 | 1.42 | 0.76 | 0.75 | 0.60 | 1.16 | 1.03 |
| Quick ratio | 0.62 | 1.10 | 1.32 | 0.83 | 1.35 | 0.71 | 0.70 | 0.55 | 1.11 | 0.99 |
| Cash ratio | 0.24 | 0.51 | 0.91 | 0.38 | 0.87 | 0.32 | 0.39 | 0.18 | 0.64 | 0.51 |
| Leverage | ||||||||||
| Debt / Equity | -0.16 | -0.15 | -0.25 | -0.43 | -20.32 | -0.50 | -0.53 | -0.34 | -0.99 | -0.60 |
| Debt / Assets | 0.19 | 0.19 | 0.15 | 0.24 | 0.18 | 0.23 | 0.28 | 0.32 | 0.19 | 0.23 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.82 | -0.79 | -1.68 | -1.84 | -111.93 | -2.14 | -1.89 | -1.07 | -5.26 | -2.65 |
| Liabilities / Assets | 2.22 | 2.27 | 1.60 | 1.54 | 1.01 | 1.47 | 1.53 | 1.94 | 1.19 | 1.38 |
| Efficiency | ||||||||||
| Asset turnover | 0.39 | - | 0.32 | 0.49 | 0.34 | - | 0.47 | 0.63 | 0.30 | - |
| Inventory turnover | 3.07 | - | 3.27 | 3.19 | 2.77 | - | 3.11 | 4.43 | 3.98 | - |
| Days sales outstanding | 264d | - | 209d | 194d | 176d | - | 203d | 212d | 260d | - |
| Days inventory outstanding | 119d | - | 112d | 115d | 132d | - | 117d | 82d | 92d | - |
| Days payable outstanding | 802d | - | 717d | 731d | 737d | - | 1032d | 708d | 639d | - |
| Cash conversion cycle | -419d | - | -397d | -423d | -428d | - | -712d | -414d | -287d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -13.7% | - | 2.1% | -3.5% | 5.9% | - | 1.8% | 0.0% | -7.0% | - |
| Revenue CAGR (3y) | -5.3% | - | 3.6% | 5.2% | 6.4% | - | 10.7% | 11.5% | 12.9% | - |
| Revenue CAGR (5y) | 5.6% | - | 13.2% | 26.4% | 13.3% | - | 11.9% | 16.9% | 21.8% | - |
| Gross profit growth (YoY) | -31.3% | - | 2.1% | 8.0% | 28.5% | - | 3.7% | -8.3% | 1.9% | - |
| Operating income growth (YoY) | 32.0% | - | 57.8% | 58.8% | 31.2% | - | 9.0% | -1.7% | 18.4% | - |
| Net income growth (YoY) | - | - | -37.9% | 24.5% | 60.0% | - | 24.6% | -52.4% | 23.7% | - |
| EPS growth (YoY) | 44.4% | - | 43.5% | 75.0% | 76.9% | - | 52.1% | 0.0% | 46.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 22.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -10245.0% | -170.5% | -72.4% | 27.6% | 95.6% | -8.4% | -282.4% | -602.5% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$9.22M totalSingle Reportable Segment$9.22M · 100.0%
Product / service
$9.22M totalProduct$9.22M · 100.0%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Aspira Women's Health Inc. against the 5 most active filers in the same SIC group.